Current Assets

Cash, Cash Equivalents, and Marketable Securities

Neurocrine Biosciences Cash, Cash Equivalents, and Marketable Securities increased by 371.5% to $1.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 398.0%, from $317.30M to $1.58B. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ2 2021
Last reportedQ1 2026May 5, 2026

How to read this metric

Higher levels provide a larger buffer for operational needs and strategic opportunities, while lower levels may indicate tight liquidity or aggressive capital deployment.

Detailed definition

This is the aggregate of all highly liquid assets, including cash, bank deposits, and short-term marketable securities t...

Peer comparison

A fundamental liquidity metric used by all public companies to assess financial health.

Metric ID: cash_equivalents_marketable_securities_total

Historical Data

7 periods
 Q2 '21Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$245.50M$458.70M$317.30M$401.80M$349.80M$335.10M$1.58B
QoQ Change+86.8%-30.8%+26.6%-12.9%-4.2%+371.5%
YoY Change-26.9%+398.0%
Range$245.50M$1.58B
CAGR+246.0%
Avg YoY Growth+185.5%
Median YoY Growth+185.5%

Cash, Cash Equivalents, and Marketable Securities at Other Companies

Frequently Asked Questions

What is Neurocrine Biosciences's cash, cash equivalents, and marketable securities?
Neurocrine Biosciences (NBIX) reported cash, cash equivalents, and marketable securities of $1.58B in Q1 2026.
How has Neurocrine Biosciences's cash, cash equivalents, and marketable securities changed year-over-year?
Neurocrine Biosciences's cash, cash equivalents, and marketable securities increased by 398.0% year-over-year, from $317.30M to $1.58B.
What does cash, cash equivalents, and marketable securities mean?
The total amount of cash and easily sellable investments the company holds.